Charlotte O Pioch, Niklas Ziegahn, Christine Allomba, Leonie M Busack, Alexandra N Schnorr, Apolline Tosolini, Bent R Fuhlrott, Styliani Zagkla, Till Othmer, Zulfiya Syunyaeva, Simon Y Graeber, Mehrak Yoosefi, Stephanie Thee, Eva Steinke, Jobst Röhmel, Marcus A Mall, Mirjam Stahl
BACKGROUND: In health, nitric oxide (NO) shows high concentrations in the upper airways, while nasal NO (nNO) is significantly lower in patients with sinonasal inflammation, such as people with cystic fibrosis (PwCF). In PwCF treated with elexacaftor/tezacaftor/ivacaftor (ETI; PwCF-ETI), clinical improvement of sinonasal symptoms and inflammation was observed. We therefore hypothesised that ETI may increase nNO in PwCF. METHODS: 25 PwCF-ETI underwent nNO measurement at baseline and after 3 to 24 months of ETI treatment...
March 19, 2024: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society